seattle, washington — Retired Major General William Anders, the former Apollo 8 astronaut who took the iconic “Earthrise” photo showing the planet as a shadowed blue marble from space in 1968, was killed Friday when the plane he was piloting alone plummeted into the waters off the San Juan Islands in Washington state. He was 90. His son, Greg Anders, confirmed the death to The Associated Press.

“The family is devastated,” Greg Anders said. “He was a great pilot, and we will miss him terribly.”

Anders said the photo was his most significant contribution to the space program, given the ecological and philosophical impact it had, along with making sure the Apollo 8 command module and service module worked.

A report came in around 11:40 a.m. local time that an older-model plane had crashed into the water and had sunk near the north end of Jones Island, San Juan County Sheriff Eric Peter said.

Only the pilot was on board the Beech A45 airplane at the time, according to the Federal Aviation Association.

William Anders said in a 1997 NASA oral history interview that he didn’t think the Apollo 8 mission was risk-free but there were important national, patriotic and exploration reasons for going ahead.

He estimated there was about a one-in-three chance that the crew wouldn’t make it back and the same chance the mission would be a success and the same chance that the mission wouldn’t start to begin with. He said he suspected Christopher Columbus sailed with worse odds.

He recounted how the Earth looked fragile and seemingly physically insignificant yet was home.

“We’d been going backwards and upside down, didn’t really see the Earth or the sun, and when we rolled around and came around and saw the first Earthrise,” he said. “That certainly was, by far, the most impressive thing. To see this very delicate, colorful orb which to me looked like a Christmas tree ornament coming up over this very stark, ugly lunar landscape really contrasted.”

The National Transportation Safety Board and FAA are investigating the crash.
…

…

…

Zimbabwe is facing long hours of power cuts due to its dilapidated infrastructure and the impact of recurring droughts on hydropower. To help, the United Nations Development Program is installing solar panels on government-owned health facilities. Columbus Mavhunga reports from Bulawayo.
…

…

Boca Chica, Texas — SpaceX’s mega Starship rocket completed its first full test flight Thursday, returning to Earth without exploding after blasting off from Texas. 

The previous three test flights ended in explosions of the rocket and the spacecraft. This time, both managed to splash down in a controlled fashion. 

The world’s largest and most powerful rocket — almost 121 meters tall — was empty as it soared above the Gulf of Mexico and headed east on a flight to the Indian Ocean. 

Minutes after Thursday morning’s liftoff, the first-stage booster separated from the spacecraft and splashed into the gulf precisely as planned, after firing its engines. 

An hour later, live views showed parts of the spacecraft breaking away during the intense heat of reentry, but it remained intact enough to transmit data all the way to its targeted splashdown site in the Indian Ocean. 

“And we have splashdown!” SpaceX launch commentator Kate Tice announced from Mission Control at company headquarters in California. 

It was a critical milestone in the company’s plan to eventually return Starship’s Super Heavy booster to its launch site for reuse. 

SpaceX came close to avoiding explosion in March, but lost contact with the spacecraft as it careened out of space and blew up short of its goal. The booster also ruptured in flight, a quarter-mile above the gulf. 

Last year’s two test flights ended in explosions shortly after blasting off from the southern tip of Texas near the Mexican border. The first one cratered the pad at Boca Chica Beach and hurled debris for thousands of feet (meters). 

SpaceX upgraded the software and made some rocket-flyback changes to improve the odds. The Federal Aviation Administration signed off Tuesday on this fourth demo, saying all safety requirements had been met. 

Starship is designed to be fully reusable. That’s why SpaceX wants to control the booster’s entry into the gulf and the spacecraft’s descent into the Indian Ocean — it’s intended as practice for planned future landings. Nothing is being recovered from Thursday’s flight. 

NASA has ordered a pair of Starships for two moon-landing missions by astronauts, on tap for later this decade. Each moon crew will rely on NASA’s own rocket and capsule to leave Earth, but meet up with Starship in lunar orbit for the ride down to the surface. 

SpaceX already is selling tourist trips around the moon. The first private lunar customer, a Japanese tycoon, pulled out of the trip with his entourage last week, citing the oft-delayed schedule. 

SpaceX’s founder and CEO has grander plans: Musk envisions fleets of Starships launching people and the infrastructure necessary to build a city on Mars. 
…

Many Israeli and Palestinian children are suffering from trauma because of the October 7 Hamas attack on Israel and the ensuing eight months of war between the two sides. Therapists in both communities say the emotional scars could linger for years. Linda Gradstein reports from Jerusalem.
…

SHANGHAI, China — Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market, where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.

The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world’s highest number of people who are overweight or obese.

Ozempic won approval from China in 2021, and Novo Nordisk saw sales of the drug in the greater China region double to $698 million last year. It is expecting Wegovy to be approved this year.

But the patent on semaglutide, the active ingredient in both Wegovy and Ozempic, expires in China in 2026. Novo is also in the midst of a legal fight in the country over the patent.

An adverse court ruling could make it lose its semaglutide exclusivity even sooner and turn China into the first major market where Novo is stripped of patent protection for the drugs.

Those circumstances have drawn several Chinese drugmakers to the fray. At least 11 semaglutide drug candidates from Chinese firms are in the final stages of clinical trials, according to records in a clinical trial database reviewed by Reuters.

“Ozempic has witnessed unprecedented success in mainland China … and with patent expiry so close, Chinese drugmakers are looking to capitalize (on) this segment as soon as possible,” said Karan Verma, a health care research and data analyst at information services provider Clarivate.

Front-runner Hangzhou Jiuyuan Gene Engineering has already developed one treatment that it says has “similar clinical efficacy and safety” as Ozempic and applied for approval for sale in April. The company has not published efficacy data and did not respond to a request for information.

The company said in January that it expected approval in the second half of 2025, but it cautioned that it would not be able to commercialize the drug before Novo’s patent expires in 2026, unless a Chinese court makes a final ruling that the patent is invalid.

The Danish company’s semaglutide patent is expiring in China far ahead of its expiry in key markets such as Japan, Europe and the U.S. Analysts attribute variations in patent expiry timelines to term extensions Novo has won in specific regions.

Even more pressing for Novo is the China patent office’s 2022 ruling that the patent is invalid for reasons related to experimental data availability, which the company has challenged.

China’s top court said it was not able to say when verdicts are likely ready.

A Novo spokesperson said it “welcomes healthy competition” and was awaiting a court decision on its patent case. The spokesperson did not answer follow-up queries on the matter.

Other Chinese drugmakers who are running the final stages of clinical trials for Ozempic generics include United Laboratories, CSPC Pharmaceutical Group, Huadong Medicine and a subsidiary of Sihuan Pharmaceutical Holdings Group.

CSPC said in May it expected approval for its semaglutide diabetes drug in 2026.

Brokerage Jefferies estimated in an October report that semaglutide drugs from United Laboratories will be launched for diabetes in 2025 and obesity in 2027. United Laboratories did not respond to a request for comment.

Impact on prices

The number of adults who are overweight or obese in China is projected to reach 540 million and 150 million, respectively, in 2030, up 2.8 and 7.5 times from 2000 levels, according to a 2020 study by Chinese public health researchers.

If shown to be as safe and effective as Novo’s, Chinese drugmakers’ products will increase competition and bring down prices, analysts say.

Goldman Sachs analysts estimated in an August report that generics could lead to a price reduction of around 25% for semaglutide in China. The weekly Ozempic injection costs around $100 for each 3mL dose through China’s public hospital network, Clarivate’s Verma said.

Novo acknowledges the intensifying competition.

“In 2026 and 2027 we might see a few more players showing up due to the clinical trials” in progress, Maziar Mike Doustdar, a Novo executive vice president, told investors in March, referring to the China market.

But he also questioned the capability of some of the players to provide meaningful volumes, adding, “We will watch it as we get closer.”

Novo also faces competition from internationally well-known firms, including Eli Lilly, whose diabetes drug Mounjaro received approval from China in May. HSBC analysts expect China’s approval this year or in the first half of 2025 for Lilly’s weight loss drug with the same active ingredient.

Eli Lilly did not reply to a request for a comment on Chinese approval of the drug, which in the U.S. is called Zepbound.

Supplies of both Wegovy and Zepbound remain constrained, but the companies have been increasing production.

Zuo Ya-Jun, general manager of weight loss drugmaker Shanghai Benemae Pharmaceutical, said a product being competitive would depend on distinguishing features such as efficacy, durability of the treatment and a company’s sales abilities.

“It will be a market with fierce competition, but who will be [the leader] is hard to say,” she said.
…

…

NEW YORK — The U.N. secretary-general said Wednesday that the world is “at a moment of truth” to reach targets in the 2015 Paris climate accord to limit global warming, as the planet has just experienced the 12 hottest consecutive months on record.

“The truth is, almost ten years since the Paris Agreement was adopted, the target of limiting long-term global warming to 1.5 degrees Celsius is hanging by a thread,” Antonio Guterres told an audience at New York’s American Museum of Natural History, where exhibits about extinct dinosaurs offered their own planetary warning.

“The World Meteorological Organization reports today that there is an 80% chance the global annual average temperature will exceed the 1.5-degree limit in at least one of the next five years,” he said.

“We are playing Russian roulette with our planet,” he warned in a special climate speech under the museum’s famous blue whale, marking World Environment Day.

The U.N. chief said the richest 1% of countries are emitting as much pollution as two-thirds of all humanity.

He said the planet is emitting around 40 billion tons of carbon dioxide annually and will burn through its remaining “carbon budget” of around 200 billion tons well before 2030. Guterres also said global emissions need to fall 9% each year between now and 2030 in order to keep the 1.5 degree Celsius limit alive. Last year, they rose by 1%.

The bill for the climate crisis will keep growing without meaningful action.

“Even if emissions hit zero tomorrow, a recent study found that climate chaos will still cost at least $38 trillion a year by 2050,” Guterres said.

Fossil fuels

The climate crisis has been a signature issue of Guterres’ tenure since becoming the world’s top diplomat seven-and-a-half years ago. He has repeatedly called for the phasing out of coal and other fossil fuels in favor of cleaner renewable energies like wind and solar power — which already produce nearly a third of the world’s electricity.

He raised the ante Wednesday, urging banks to stop financing oil, coal and gas and invest in renewables instead. He called on countries to ban advertising from fossil fuel producers and said news and technology platforms should stop taking their advertising.

“I call on leaders in the fossil fuel industry to understand that if you are not in the fast lane to clean energy transformation, you are driving your business into a dead end — and taking us all with you,” the U.N. chief said, adding that the oil and gas industry invested only 2.5% of its total spending on clean energy in the last year.

He urged public relations companies and lobbyists to stop enabling the industry’s “planetary destruction” and drop those clients.

“Many in the fossil fuel industry have shamelessly greenwashed, even as they have sought to delay climate action — with lobbying, legal threats, and massive ad campaigns,” he said.

Leveling the field

The secretary-general reiterated his stance that those who have contributed the least to the climate crisis are suffering the most — mainly poorer nations in Africa and small island states. The G20 major economies produce 80% of the world’s emissions.

“It is a disgrace that the most vulnerable are being left stranded, struggling desperately to deal with a climate crisis they did nothing to create,” he said.

Guterres warned that the difference between 1.5 and 2 degrees could mean survival or extinction for some small island nations and coastal communities.

“1.5 degrees is not a target. It is not a goal. It is a physical limit,” he said.

Global warming is already hurting the planet’s oceans, their coral reefs and marine ecosystems, and melting sea ice. Across the globe, severe floods, droughts, heatwaves, wildfires, and other climate-related catastrophes are becoming all too frequent.

The secretary-general said there must be more financing and technical support from richer countries to mitigate climate impacts and invest in renewables for lower income states. He also said a global early warning system must be in place by 2027, to protect everyone on Earth from hazardous weather, water or climate events.

He urged citizens to continue to make their voices heard and said it is time for leaders to decide whose side they are on.

“Now is the time to mobilize; now is the time to act; now is the time to deliver,” he said to a standing ovation. “This is our moment of truth.”
…

…

washington — Federal health advisers voted Tuesday against a first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD, handing a potentially major setback to advocates who had hoped to win a landmark federal approval and bring the banned drugs into the medical mainstream. 

The panel of advisers to the Food and Drug Administration sided 10-1 against the overall benefits of MDMA when used to treat post-traumatic stress disorder. They cited flawed study data, questionable research conduct and significant drug risks, including the potential for heart problems, injury and abuse. 

“It seems like there are so many problems with the data — each one alone might be OK, but when you pile them on top of each other … there’s just a lot of questions I would have about how effective the treatment is,” said Dr. Melissa Decker Barone, a psychologist with the Department of Veterans Affairs. 

The FDA is not required to follow the group’s advice and is expected to make its final decision by August, but the negative opinion could strengthen FDA’s rationale for rejecting the treatment. 

The vote followed hours of pointed questions and criticisms about the research submitted on MDMA — sometimes called ecstasy or molly. Panelists pointed to flawed studies that could have skewed the results, missing follow-up data on patient outcomes, and a lack of diversity among participants. The vast majority of patients studied were white, with only five Black patients receiving MDMA, raising questions about the generalizability of the results. 

“The fact that this study has so many white participants is problematic because I don’t want something to roll out that only helps this one group,” said Elizabeth Joniak-Grant, the group’s patient representative. 

The FDA advisers also drew attention to allegations of misconduct in the trials that have recently surfaced in news stories and a report by the nonprofit Institute for Clinical and Economic Review, which evaluates experimental drug treatments. The incidents include a 2018 report of apparent sexual misconduct by a therapist interacting with a patient. 

Lykos Therapeutics, the company behind the study, said it previously reported the incident to the FDA and regulators in Canada, where the therapist is based. Lykos is essentially a corporate spinoff of the nation’s leading psychedelic advocacy group, the Multidisciplinary Association for Psychedelic Studies, or MAPS, which funded the studies. The group was founded in 1986 to promote the benefits of MDMA and other mind-altering substances. 

MDMA is the first in a series of psychedelics — including LSD and psilocybin — that are expected to come before the FDA in the next few years. The panel’s negative ruling could further derail financial investments in the fledgling industry, which has mainly been funded by a small number of wealthy backers. 

MDMA’s main effect is triggering feelings of intimacy, connection and euphoria. When used to enhance talk therapy, the drug appears to help patients process their trauma and let go of disturbing thoughts and memories. 

But the panel struggled with the reliability of those results, given the difficulties of objectively testing psychedelic drugs. 

Because MDMA causes intense, psychological experiences, almost all patients in two key studies of the drug were able to guess whether they had received the MDMA or a dummy pill. That’s the opposite of the approach generally required for high-quality drug research, in which bias is minimized by “blinding” patients and researchers to whether they received the drug under investigation. 

“I’m not convinced at all that this drug is effective based on the data I saw,” said Dr. Rajesh Narendran, a University of Pittsburgh psychiatrist who chaired the panel. 

Panelists also noted the difficulty of knowing how much of patients’ improvement came from MDMA versus simply undergoing the extensive therapy, which totaled more than 80 hours for many patients. Results were further marred by other complicating factors, including a large number of patients who had previously used MDMA or other psychedelics drugs recreationally. 
…

…

…

…